AG003QL2

65646-68-6 | N-(4-Hydroxyphenyl)retinamide

AG003QL2

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	65646-68-6
Catalog Number	AG003QL2(AGN-PC-0THJ9T)
Chemical Name	N-(4-Hydroxyphenyl)retinamide
IUPAC Name	(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
InChI	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
InChI Key	AKJHMTWEGVYYSE-FXILSDISSA-N
MDL Number	MFCD00792674
Molecular Formula	C26H33NO2
Molecular Weight	391.5457
SMILES	OC1=CC=C(C=C1)NC(\C=C(\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C)/C)=O
UNII	187EJ7QEXL
Synonyms	13-cis-Isomer Fenretinide, 4 Hydroxyphenylretinamide, 4-HPR, 4-Hydroxyphenylretinamide, Fenretinide, Fenretinide, 13 cis Isomer, Fenretinide, 13-cis-Isomer, Fenretinimide, MCN R 1967, MCN-R-1967, MCNR1967, N-(4-Hydroxyphenyl)-trans-Retinamide, N-(4-Hydroxyphenyl)retinamide, FENRETINIDE, 65646-68-6, N-(4-Hydroxyphenyl)retinamide, 4-HPR, 4-hydroxyphenylretinamide, 4-Hydroxyphenyl retinamide, Retinoic acid p-hydroxyanilide, all-trans-4'-Hydroxyretinanilide, Fenretinida, Fenretinidum, McN-R-1967, 4-hydroxy(phenyl)retinamide, N-(4-Hydroxyphenyl)all-Trans Retinamide, Fenretinidum [Latin], Fenretinida [Spanish], 4HPR, Retinoic acid p-hydroxyphenylamide, Fenretinide [USAN:INN], Retinamide, N-(4-hydroxyphenyl)-, UNII-187EJ7QEXL, 4-(hydroxyphenyl)retinamide, 15-[(4-hydroxyphenyl)amino]retinal, CCRIS 3260, MFCD00792674, BRN 5769490, 187EJ7QEXL, CHEMBL7301, MLS002701698, CHEBI:42588, AKJHMTWEGVYYSE-FXILSDISSA-N, NSC-374551, NCGC00090752-03, N-(4-Hydroxyphenyl)-all-trans Retinamide, DSSTox_CID_12005, DSSTox_RID_78900, DSSTox_GSID_32005, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide, Fenretinimide, (2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide, SMR001456303, CAS-65646-68-6, SR-01000075917, SYT-101, ST-602, N-(4-Hydroxyphenyl)-trans-Retinamide, Fenretinide (4-HPR), p-Hydroxyphenylretinamide, AC1NRB1E, Spectrum5_001939, Fenretinide (USAN/INN), AC1Q1QV3, 4 HPR, Lopac0_000625, SCHEMBL11703, SCHEMBL11704, BSPBio_001419, MLS001055399, MLS006010811, BML2-E08, N-(4-hydroxyphenyl)-retinamide, DTXSID2032005, SCHEMBL15703189, CHEBI:92493, AOB6402, Retinamide,N-(4-hydroxyphenyl)-, 15-(4-Hydroxyanilino)retinal #, HMS1361G21, HMS1791G21, HMS1989G21, HMS2089B17, HMS3261N12, HMS3402G21, HMS3676M06, Pharmakon1600-01505602, (2Z,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, 4-HPR;(4-Hydroxyphenyl)retinamide, BCP06908, ZINC3871023, Tox21_111007, Tox21_200989, Tox21_500625, 1-enyl)nona-2,4,6,8-tetraenamide, 3670AH, BDBM50092055, HSCI1_000112, LS-282, NSC374551, NSC760419, AKOS024456572, Tox21_111007_1, AN-7467, CCG-204713, CS-0789, DB05076, LP00625, MK-4016, N-(4-hydroxyphenyl)retinamide, 4-HPR, NSC-760419, all-trans-n-(4-hydroxyphenyl)retinamide, dimethyl-9-(2,6,6-trimethylcyclohex-, IDI1_033889, Retinoic acid p-hydroxyanilide, >=95%, NCGC00090752-01, NCGC00090752-02, NCGC00090752-04, NCGC00090752-05, NCGC00090752-06, NCGC00090752-07, NCGC00090752-09, NCGC00090752-10, NCGC00090752-11, NCGC00090752-12, NCGC00258542-01, NCGC00261310-01, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide, BP-13369, HY-15373, SC-76490, SMR000677938, AB0109574, EU-0100625, FT-0081247, A12163, D04162, H 7779, W-5119, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-, 33819-EP2275420A1, 33819-EP2295055A2, 33819-EP2295406A1, 33819-EP2295416A2, 33819-EP2295426A1, 33819-EP2295427A1, 33819-EP2298748A2, 33819-EP2298764A1, 33819-EP2298765A1, 33819-EP2305642A2, 33819-EP2311453A1, 33819-EP2311808A1, 33819-EP2311829A1, AB00172992-07, 646F686, A835178, SR-01000075917-1, SR-01000075917-4, 4-(HYDROXYPHENYL)-RETINAMIDE (SEE RETINOID PROJECTS 1 AND 2.), RETINOID PROJECT 6 (4-HPR) (SEE RETINOID PROJECTS 1,2,3,4,5), RETINOID PROJECT 2 (4-(HYDROXYPHENYL)RETINAMIDE) (SEE RETINOID PROJECT 1,3,4, 5,6), RETINOID PROJECT 4 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, AND 3), RETINOID PROJECT 5 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, 3, 4), (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide, 2,6,8-Nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-E)-, 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide, N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraeneamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide, RETINAMIDE, Methyl 4-fluorobenzoate, 4 Hydroxyphenylretinamide, 13-cis-Isomer Fenretinide, D08JAC, LXS/4-HPR, C26H33NO2, Fenretinide, 13 cis Isomer, Fenretinide, 13-cis-Isomer, MCNR1967, Fenretinide (oral, AMD), Sytera, MCN R 1967, C26-H33-N-O2, RT-101, CID5288209, Fenretinide (iv), Children's Hospital LA, H1464, Fenretinide (soft gel capsule, AMD), Sirion, D017313, Fenretinide (Ewing's sarcoma), Cancer Research UK, Fenretinide (ILE formulation), Children's Hospital LA, Fenretinide (intravenous, cancer), SciTech Development, HPR, Fenretinide (soft gel capsule, AMD), ReVision Therapeutics, Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products, Fenretinide (topical, actinic keratosis and cancer), SciTech Development, Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles, FEN, Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx, Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University,

Complexity	726
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	4
Exact Mass	391.251g/mol
Formal Charge	0
Heavy Atom Count	29
Hydrogen Bond Acceptor Count	2
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	391.555g/mol
Monoisotopic Mass	391.251g/mol
Rotatable Bond Count	6
Topological Polar Surface Area	49.3A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	7.3

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302+H312+H332-H315-H319-H335
Packing Group
Precautionary statements	P261-P280-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number